Stopping TKI in CML after asciminib
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been taking a TKI (imatinib, nilotinib, or dasatinib) for at least 5 years.
- You have tried to stop your TKI before and lost deep remission, but then restarted your TKI and regained deep remission for at least 12 weeks.
- You must agree to stop your TKI and switch to asciminib if you reach a very deep remission (MR4.5) and maintain it for 23 years.
- Your liver and kidney function must be good enough (based on blood tests).
- You have not had serious side effects from TKIs, uncontrolled infections, or certain heart or blood-clot problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.